Désiré Collen launched a new biotech fund, Fund+. The founder of Thrombogenics collected money from Urbain Vandeurzen, AB InBev billionaire Arnaud de Pret and government funds. The ambition of Désiré Collen is to gather 100 million euro to invest in Belgian biotech companies: “Thusfar only 18,5 million is available, but agreements for 60 million euros have been made. Also, 20 million euros have been promised within one month. This means that 100 million euros is close. We keep the number of investors deliberately limited and we are working with big-ticket investments of 2 to 10 million euros.” Collen, who is currently the chairman of the fund, hopes to make a real difference.
BioVox
With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!
All posts